Search Within

Goutam Chakraborty

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (23)
  2. Meeting Abstract (22)
Groups
  1. Sloan Kettering Institute Postdocs (45)
  2. Department of Medicine (34)
  3. Genitourinary Oncology Service (34)
  4. Solid Tumor Oncology Division (34)
  5. GSK Faculty (16)
  6. Human Oncology and Pathogenesis Program (9)

More Groups

People
  1. Philip Kantoff (29)
  2. Ying Mazzu (27)
  3. Yuki Yoshikawa (22)
  4. Subhiksha Nandakumar (20)
  5. Mohammad Atiq (14)
  6. Joshua Armenia (13)

More People

Years
  1. 2024 (2)
  2. 2022 (4)
  3. 2021 (5)
  4. 2020 (7)
  5. 2019 (12)
  6. 2018 (7)

More Years

Publications
  1. Cancer Research (10)
  2. Journal of Clinical Oncology (10)
  3. Clinical Cancer Research (4)
  4. Expert Opinion on Therapeutic Targets (3)
  5. Journal of Nuclear Medicine (3)
  6. Cell (2)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. American Society of Clinical Oncology (10)
  3. Cell Press (4)
  4. Informa Healthcare (3)
  5. Society of Nuclear Medicine (3)
  6. FEBS Press (2)

More Publishers

Results (45)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression
    Meeting Abstract

    Mazzu, Y. Z.; Armenia, J.; Chakraborty, G.; Yoshikawa, Y.; Gerke, T. A.; Atiq, M. O.; Stopsack, K. H.; Komura, K.; Lee, G. S. M.; Mucci, L. A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • BRCA2-RB1 co-loss and ADT resistance in aggressive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Armenia, J.; Mazzu, Y. Z.; Stopsack, K. H.; Atiq, M. O.; Chadalavada, K.; Nanjangud, G.; Khan, N.; Komura, K.; Yoshikawa, Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer
    Meeting Abstract

    Mazzu, Y. Z.; Gerke, T. A.; Chakraborty, G.; Armenia, J.; Atiq, M. O.; Komura, K.; Yoshikawa, Y.; Lee, G. S. M.; Mucci, L. A.; Kantoff, P. W.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Concurrent deletion of BRCA2 and RB1 and aggressive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Armenia, J.; Mazzu, Y. Z.; Nanjangud, G.; Chadalavada, K.; Atiq, M. O.; Komura, K.; Yoshikawa, Y.; Khan, N.; Du, S. Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Targeting poor-prognosis subtypes of prostate cancer by inhibition of DNA repair gene ribonucleotide reductase small subunit M2
    Meeting Abstract

    Mazzu, Y. Z.; Armenia, J.; Chakraborty, G.; Yoshikawa, Y.; Gerke, T. A.; Coggins, S. A. A.; Qiu, X.; Atiq, M.; Stopsack, K. H.; Lee, G. S. M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Signaling by discoidin domain receptor 1 in cancer metastasis
    Journal Article

    Gadiya, M.; Chakraborty, G.
    Cell Adhesion & Migration (2018)

    Fulltext@MSK | Save
  • ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
    Journal Article

    Komura, K.; Yoshikawa, Y.; Shimamura, T.; Chakraborty, G.; Gerke, T. A.; Hinohara, K.; Chadalavada, K.; Jeong, S. H.; Armenia, J.; Du, S. Y.; more...
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling
    Journal Article

    Gao, H.; Chakraborty, G.; Zhang, Z.; Akalay, I.; Gadiya, M.; Gao, Y.; Sinha, S.; Hu, J.; Jiang, C.; Akram, M.; more...
    Cell (2016)

    Fulltext@MSK | Save
  • Inactivation of neogenin promotes castration resistance and bone metastasis in prostate cancer models
    Meeting Abstract

    Chakraborty, G.; Gadiya, M.; Kossai, M.; Gao, D.; Su, W. J.; Gao, H.; Chen, Y.; Scher, H. I.; Rubin, M. A.; Giancotti, F.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis
    Journal Article

    Mishra, R.; Thorat, D.; Soundararajan, G.; Pradhan, S. J.; Chakraborty, G.; Lohite, K.; Karnik, S.; Kundu, G. C.
    Oncogene (2015)

    Fulltext@MSK | Save